Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral: Vanier Canada Graduate Scholarships

McMaster University

$150,000.00

Elucidating the relationship between molecular biomarkers of aging and metabolic multimorbidity

FY 2021-22

Summary
Our healthcare system is overburdened by the increasing prevalence of metabolic multimorbidity, a condition characterized by the co-occurrence of different, yet related, metabolic diseases. Approximately 3.5% of Canadians above the age of 50 live with cardiometabolic multimorbidity and 19% of Canadian adults are diagnosed with metabolic syndrome which increases the risk of developing multimorbidity. While traditional therapies have been developed to treat diseases separately, there is an emergent need for therapies that can target underlying factors causing interrelated metabolic diseases. Many biomarkers have been discovered as potential pharmacotherapy candidates, yet past studies have failed to distinguish between causality and association due to methodological and resource limitations. Recently, two molecular biomarkers of aging, namely clonal hematopoiesis of indeterminate potential and epigenetic age, have been discovered to predict all-cause mortality, cardiovascular diseases, and type 2 diabetes. These biomarkers are characterized by unique genetic mutations and epigenetic patterns. However, the strength of their relationship to metabolic multimorbidity as it pertains to causality remains unknown. The proposed study will employ a rare multimodal strategy using a comprehensive set of cutting-edge molecular data, integrated with clinical and demographic data, from two international epidemiological studies (PURE and ORIGIN) totaling over 200,000 participants to characterize the relationship between molecular biomarkers of aging and combinations of metabolic multimorbidity. The demographic heterogeneity of our large study population, including both healthy and unhealthy populations, will broaden the relevance of our findings among the general population. Should our hypothesis be confirmed, these novel biomarkers will inform risk stratification for patients and form the basis for new therapies that can comprehensively treat or prevent metabolic multimorbidity.
Program
Doctoral: Vanier Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
457493
Name
Wu Jianhan
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Elucidating the relationship between molecular biomarkers of aging and metabolic multimorbidity
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Aging; Bioinformatics; Biomarkers; Epigenetics; Genetic Epidemiology; Metabolic Multimorbidity
Abstract
Our healthcare system is overburdened by the increasing prevalence of metabolic multimorbidity, a condition characterized by the co-occurrence of different, yet related, metabolic diseases. Approximately 3.5% of Canadians above the age of 50 live with cardiometabolic multimorbidity and 19% of Canadian adults are diagnosed with metabolic syndrome which increases the risk of developing multimorbidity. While traditional therapies have been developed to treat diseases separately, there is an emergent need for therapies that can target underlying factors causing interrelated metabolic diseases. Many biomarkers have been discovered as potential pharmacotherapy candidates, yet past studies have failed to distinguish between causality and association due to methodological and resource limitations. Recently, two molecular biomarkers of aging, namely clonal hematopoiesis of indeterminate potential and epigenetic age, have been discovered to predict all-cause mortality, cardiovascular diseases, and type 2 diabetes. These biomarkers are characterized by unique genetic mutations and epigenetic patterns. However, the strength of their relationship to metabolic multimorbidity as it pertains to causality remains unknown. The proposed study will employ a rare multimodal strategy using a comprehensive set of cutting-edge molecular data, integrated with clinical and demographic data, from two international epidemiological studies (PURE and ORIGIN) totaling over 200,000 participants to characterize the relationship between molecular biomarkers of aging and combinations of metabolic multimorbidity. The demographic heterogeneity of our large study population, including both healthy and unhealthy populations, will broaden the relevance of our findings among the general population. Should our hypothesis be confirmed, these novel biomarkers will inform risk stratification for patients and form the basis for new therapies that can comprehensively treat or prevent metabolic multimorbidity.
Competitiondate
202111
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Wu, Jianhan
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~
McMaster University - $150,000 Grant (2021-22) | Canada Spends